On this Precision Medicine Podcast , author and CEO of the Toft Group (a ZRG company), Robin Toft, joins us to discuss her new book, We Can, and share her thoughts on the need for more women and greater diversity in the C-suite and the boardroom within the life science industry. Read the full summary here .
Roy Smythe, M.D, explains why proteins are more useful than genes for understanding the human body and creating precision medicines to heal it. Dr. Smythe is CEO of SomaLogic , a leading-edge, biotechnology company headquartered in Boulder, Colorado. The company scans human proteins to gain insights into the past, current, and future health of patients, making it a promising new technology for precision medicine outcomes. Tune in here for the full summary and more : https://www.trapelohealth.com...
In this Precision Medicine Podcast episode , we met with lung cancer patients Lisa Goldman and Tori Tomalia to discuss their organization, the ROS1ders , which they created to advocate and support those with ROS1-positive cancer—a group that represents just 2% of lung cancer patients. We were fascinated by how two women with no medical background could form a highly respected and resourceful group for those with this rare type of cancer. The women told us that when they and a mutual friend Janet...
In our second podcast with Dr. John Quackenbush, Chair of the Department of Biostatistics at Harvard University's T.H. Chan School of Public Health, we delved deeper into his approach to understanding cancer by studying entire gene networks rather than simple mutations. Read the full summary here , subscribe and learn more about our lead sponsor Trapelo Health.
In this episode of The Precision Medicine Podcast , we speak with Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Director of Research for the Cancer Treatment Centers of America in Philadelphia, about how precision medicine is changing the treatment of GI cancers. Learn about the personal experiences that inspired his medical career focus and the hidden talent that nearly stole him away.
In this episode 32 of the Precision Medicine Podcast sponsored by Trapelo, we talk extensively with Barbara Fortini, PhD, the Program Director for the Master of Science in Human Genetics and Genomic Data Analytics program at the Keck Graduate Institute about what students of biology and genetics need to know today versus what they needed to know a decade ago, and how she sees those skills being applied in a clinical setting. Read the full summary, download the transcript and tune in here . Learn...
Dr. Adam Brufsky, Medical Director for the Women’s Cancer Program at the UPMC Hillman Cancer Center, shares the newest findings from the San Antonio Breast Cancer Symposium (SABCS) and discusses the important role of precision medicine in breast cancer care. Tune in and #Subscribe here https://bit.ly/2sT9y8r #PrecisionMedicinePodcast #SABC19
In this first episode of season two of the Precision Medicine Podcast, Dr. John Quackenbush discusses his approach to understanding what makes cancer cancer by studying entire gene networks rather than simple mutations. Dr. Quackenbush is Chair of the Department of Biostatistics at Harvard University's T.H. Chan School of Public Health and one of the first people to have worked on the Human Genome Project . Read our full summary and tune in to the episode here ....
In this episode, we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio, who led a panel at the Precision Medicine Leadership Summit in Philadelphia. The panel discussion, Precision Medicine Clinical Trials and Novel Designs: Levering Data, ‘Omics’, AI and Policy focused on the importance of increasing patient accessibility to clinical trials, an issue that drove Dr. Kurnaz to cofound her company. Read more in our full summary and tune in to the episode here....
In this episode, we talk with Kristine Ashcraft, founder and CEO of YouScript, a platform that synthesizes all evidence impacting drug response, including pharmacogenetic testing, to support doctors and pharmacists in making faster, more proactive decisions at the point of care. For a summary and transcript visit https://bit.ly/2O5Fpuj
Dr. Bruce Johnson, Chief Clinical Research Officer from the Dana Farber Cancer Institute, joins us to discuss how recent advances in treating rare cancers can help drive the understanding and expansion of precision medicine.
To celebrate our upcoming anniversary, we're going back to where the Precision Medicine Podcast made its debut nearly one year ago. Dr. Edward Abrahams is President of the Personalized Medicine Coalition (PMC) and host of the 15th Annual Personalized Medicine Conference coming up on November 13 at Harvard Medical School. In this episode, we discuss the evolution of precision medicine and the value it can bring to all stakeholders, including innovators, scientists, patients, providers, and payers...
In honor of breast cancer awareness month, Dr. Erica Stringer-Reasor joins us to discuss how breast cancer has led the way in the adoption of precision medicine. Dr. Stringer-Reasor is an expert in the field of breast cancer, a fast-rising star in cancer research and Assistant Professor of Hematology Oncology at the University of Alabama, Birmingham.
In this podcast, Nigel Russell, Founder and Co-president of the Journal of Precision Medicine and host of the Precision Medicine Leadership Summit, joins us to talk about how his team communicates the importance and challenges of Precision Medicine to a broad and sometimes under-informed readership.
In Part Two of our two-part interview with Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center, we discuss the differences between how community oncologists are applying—or in many cases not applying—precision medicine as opposed to how it is applied by academic oncologists.
Ten-year cancer survivor and patient advocate Randall Broad, shares his personal story with stage III non-small cell lung cancer and how that experience made him acutely aware of the need for improved communication between patients and physicians in an effort to facilitate mutual understanding and better outcomes. Listen here.
Dr. Michael Kolodziej is CIO at ADVI Health and a pioneer in developing value-based reimbursement models for cancer care. Having seen him present his talk, “The Healthcare Landscape of 2025: 3 Trends That Can Change Cancer Care Forever,” at a Florida Association of Clinical Oncology (FLASCO) event, we were anxious to dive deeper into the trends here on the Precision Medicine Podcast. In this part two podcast, he talks about payer reform and alternative payer models in cancer care today....
Mr. Chet Burrell, former president and CEO of Care First Blue Cross Blue Shield and Executive Chairman of the Intervention Insights Board of Directors, discusses the challenges payers face in managing the growth of precision medicine for cancer care and why he's championing Trapelo's precision diagnostic platform as the first collaborative technology solution.
In this first episode with Dr. Jack West, we discuss the state of precision oncology and the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.
In this first episode with Dr. Jack West, we discuss the state of precision oncologyand the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.
Laboratories could be considered the epicenter of the precision medicine industry, so we were thrilled to have Dr. Michael Astion, Medical Director for the Department of Laboratories at Seattle Children's Hospital join us. In this episode, he introduces us to PLUGS , (Patient Centered Laboratory Utilization Guidance Service) a grassroots program he co-founded that exists to promote and strengthen laboratory stewardship.
We’ve received many questions about the challenges clinicians face in knowing when to use pharmacogenetic tests in practice. So we invited our resident "genome educator" back! Inthis episodeJeanette McCarthy, co-founder of Precision Medicine Advisors, returns to address those questions and discuss some of the issues health care providers face. Listen here.
Dr. Michael Kolodziej is Vice President and Chief Innovation Officer at ADVI Health, a Washington, D.C.-based healthcare consulting and strategy firm, and a pioneer in developing value-based reimbursement models for cancer care. Having seen him present his talk, “The Healthcare Landscape of 2025: 3 Trends That Can Change Cancer Care Forever,” at a Florida Association of Clinical Oncology (FLASCO) event, we were anxious to revisit his thinking on the subject. In this podcast, we start with the fi...
Dr. Windy Dean-Colomb, an MD Anderson-trained MD, PhD, and practicing medical oncologist, and Dr. Clayton Yates, a professor of biology at Tuskegee University and director of the university's Multidisciplinary Center for Biomedical Research, join us to discuss the importance of studying and addressing racial disparities in oncology.
How precision medicine is moving oncologists away from population-based treatments to more patient-appropriate care. Dr. Lee Newcomer, board-certified oncologist and former SVP of oncology and genetics at UnitedHealthcare, answers pressing questions about the current costs of cancer care, how diagnostics are currently reimbursed and who should control the development of those diagnostics. His answers gave us a lot to think about.
Precision Medicine Podcast guest Dr. Sandeep “Bobby” Reddy talks about how he became an early adopter of precision medicine and the opportunities that exist to present its economic benefits. Listen to the full episode here .
In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care. This episode is Part Two of that discussio...
Clynt Taylor, CEO of Intervention Insights, shares his insight in working with large cancer centers to identify and address barriers to precision medicine in cancer care.
In this episode, we welcome guest, Chris Wells, VP of Public Affairs for the Personalized Medicine Coalition, a collaboration of innovators, scientists, patients, providers, and payers who work to further the understanding and adoption of personalized medicine across the healthcare system.
Luba Greenwood, J.D., Strategic Business Development at Google Life Sciences, discusses innovative digital health tools in precision medicine and the greater healthcare space.
